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A corrigendum on
A Quantitative Assessment of Factors Affecting the Technological Development and Adoption
of Companion Diagnostics
by Luo, D., Smith, J. A., Meadows, N. A., Schuh, A., Manescu, K. E., Bure, K., et al. (2015). Front.
Genet. 6:357. doi:10.3389/fgene.2015.00357
With regards to Figure 3: Significant relationships and non-significant relationships for CDx price,
the graph (A) of CDx Price vs. CDx Sensitivity as well as the corresponding legend, is in error.
Graph A wrongly depicts a trendline unadjusted for outlier effect, and the correct graph, as
described in the text, is shown below. The corresponding legend has been likewise corrected to
reflect the correct graph title and statistical values described in the text. This correction does not
affect the scientific validity of the results, as the discrepancy was with the presentation of results.
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FIGURE 3 | Significant relationships and non-significant relationships for CDx price. (A) There is a significant relationship between CDx price and CDx
sensitivity (R2 = −0.10, p = 0.04). (B) There are non-significant relationships between CDx price and drug price (R2 = 0.043, p = 0.70) and (C) the total patient
population (R2 = 0.105 p = 0.59).
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